All News
Featured Abstracts from Industry at EULAR 2021
Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports. Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections
The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.
Read ArticleLinks:
Congress Slams AbbVie Over Price Hikes, 'Frivolous' Patents
House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.
Read ArticleRheumNow Podcast – Myth Busters (5.21.2021)
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read ArticleLinks:
Lower Rates of Serious Infection with Ustekinumab in Psoriatic Disease
Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.
Read ArticleJilaine Bolek Berquist BolekBerqui ( View Tweet)
IL-23 Inhibitor Tildrakizumab Effective in Psoriatic Arthritis
Tildrakizumab, a monoclonal antibody targeting interleukin-23p19 studied in adults with psoriatic arthritis (PsA), was found to be superior to placebo and well tolerated without reports of uveitis, systemic fungal infections, inflammatory bowel disease, major cardiac events or death.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2021 Now Available for All
RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).
Read ArticleNSAID Safety with COVID-19 Infection
NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.
Read ArticleInsurers Bet Big on Bribing Patients
Last month, psoriasis patients covered by Cigna received a curious letter from the insurance giant's pharmacy management division.
Read ArticleRheumNow Podcast – Falling or Falling in Love?
Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.
Read ArticleDrug Monitoring Ineffective with Infliximab Treatment
The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.
Read ArticleLinks:
Dr. John Cush RheumNow ( View Tweet)